1046P First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)

Abstract

Anti-PD-1 antibody monotherapy (PD1) leads to favorable responses in advanced cutaneous melanoma (CM) among Caucasian populations; however, recent studies have indicated limited efficacy in mucosal melanoma (MM) than in CM. Thus, advanced MM patients (pts) are candidates for anti-PD-1 plus anti-CTLA-4 combination therapy (PD1+CTLA4). Meanwhile, data on the efficacy of immunotherapy in MM are limited. We aimed to compare the efficacies of first-line PD1 and PD1+CTLA4 in Japanese advanced MM pts in the real-world setting.